Who are INS365 Ophthalmic Solution's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ins365-ophthalmic-solution.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

INS365 Ophthalmic Solution — Competitive Intelligence Brief

INS365 Ophthalmic Solution (INS365 Ophthalmic Solution) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: IP3 receptor antagonist. Area: Ophthalmology.

phase 3 IP3 receptor antagonist IP3 receptor (inositol 1,4,5-trisphosphate receptor) Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

INS365 Ophthalmic Solution (INS365 Ophthalmic Solution) — Merck Sharp & Dohme LLC. INS365 is a small-molecule selective inhibitor of inositol 1,4,5-trisphosphate (IP3) receptors that reduces intracellular calcium signaling in ocular surface cells.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
INS365 Ophthalmic Solution TARGET	INS365 Ophthalmic Solution	Merck Sharp & Dohme LLC	phase 3	IP3 receptor antagonist	IP3 receptor (inositol 1,4,5-trisphosphate receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (IP3 receptor antagonist class)

Merck Sharp & Dohme LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). INS365 Ophthalmic Solution — Competitive Intelligence Brief. https://druglandscape.com/ci/ins365-ophthalmic-solution. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab